



SCIENTIFIC PROGRAMME

17.30 - 19.30 HALL TYROL

Music

L. van Beethoven (1770 - 1827) - European Anthem
J. Brahms (1833 - 1897) - Academic Festival Overture

Welcome addresses

President of EUROMEDLAB 2009

Mathias M. Müller

Chair of the EUROMEDLAB 2009 Scientific Programme Committee

Oswald Wagner

President of the Austrian Society of Laboratory Medicine and Clinical Chemistry (ÖGLMKC)

Alexander C. Haushofer

President of the European Federation of Clinical Chemistry and Laboratory Medicine (EFCC)

Mike Hallworth

President of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC)

Graham Beastall

Vice-Rector of Innsbruck Medical University

Manfred P. Dierich

Music

Josef Strauss (1827 - 1870) - Music of the Spheres
Johann Strauss (1825 - 1899) - Elfen a Magyaren

EFCC-Roche Award to Rob T. P. Jansen (The Netherlands)

Mike Hallworth

IFCC-Abbott Award to Eleftherios P. Diamandis (Canada)

Graham Beastall

Opening new horizons in healthcare

Severin Schwan (Austria)

Music

Johann Strauss (1825 - 1899) - Moulinet Polka
Wiener Blut

Conductor: *Martin Sieghart*
Orchestra: *Haydn Orchestra Bozen-Trient*

OPENING NEW HORIZONS IN HEALTHCARE

Severin Schwan (Austria)

Chief Executive Officer - F. Hoffman - La Roche Ltd.



Nationality: Austrian

Studies

Economics at University of Innsbruck, University of York and University of Oxford

Mag. rer. soc. oec. (Innsbruck, 1991)

Law at University of Innsbruck

Mag. iur. (Innsbruck, 1991)

Doctorate in Law at University of Innsbruck

Research studies at University Louvain, Belgium

Dr. iur. (Innsbruck, 1993)

Professional Career

1993 - 1995:

Trainee at Corporate Finance, Roche Basel

1995 - 1998:

Head Finance & Administration, Roche Brussels

1998 - 2000:

Head Finance & Informatics at Roche Grenzach, Germany and Member of the Executive Board of Roche Deutschland Holding GmbH

2000 - 2004:

Head Global Finance & Services, Roche Diagnostics, Basel

2004 - 2006:

Head Region Asia Pacific, Roche Diagnostics Singapore

2006 - 2008:

Chief Executive Officer, Division Roche Diagnostics

since 2008:

Chief Executive Officer, Roche Group

After the Opening Ceremony, you are kindly invited

to take part in the informal Get-together Party.


Traditional folkloristic companies will guide you from the Congress Centre to the old town.

In front of the Golden Roof a brass band will play traditional tyrolian/austrian music and a folkloristic company will show traditional dances (Schuhplatter) on stage.

All delegates and accompanying persons registered for the congress are admitted this the Informal Get-together party.

In their Congress badge, delegates will find four vouchers (€5,00 each) which will be accepted as currency by the defined restaurants within the old town and the surrounding area.

Those restaurants will be listed in the programme leaflet of the Opening Ceremony.



11
e
J
u
n
e
7
S
u
n
d
a
y

Room FREIBURG 1

9.00-17.30 Closed Meeting
EFCC Executive Board

Room FREIBURG 2

9.00-13.00 Closed Meeting
IFCC Executive Board

Room FREIBURG 2

13.00-17.30 Closed Meeting
IFCC Working Group on
Carbohydrate - Deficient Transferrin
Chair: Dr. A. Helander

Room GRENOBLE

9.00-13.00 Closed Meeting
IFCC Committee on Public
Relations
Chair: Dr. K. Adeli

Room NEW ORLEANS

9.00-13.00 Closed Meeting
IFCC Committee on Congresses
and Conferences
Chair: Prof. T. Ozben

Room AALBORG

9.00-13.00 Closed Meeting
IFCC Educational and
Management Division
Chair: Ms. J. Smith

Room NEW ORLEANS

14.30-17.30 Closed Meeting
EFCC Working Group on
Accreditation and ISO/CEN
Standards
Chair: Dr. W. Huisman

Room AALBORG

15.00-18.00 Closed Meeting
IFCC Working Group on HbA2
Chair: Dr. A. Mosca

Room GRENOBLE

15.30-17.00 IFCC Open Meeting
Adding value to laboratory
medicine
Chair: Dr. G. Beastall

Hall TYROL

CARDIOVASCULAR DISEASES

Chair: H.A. Katus (Germany)

9.30-10.00

Quo vadis - The perspective of biomarker testing in cardiovascular disease

H.A. Katus (Germany)

10.00-10.30

Ultrasensitive cardiac troponin assays - Diagnosis of acute myocardial infarction and beyond
E. Giannitsis (Germany)

10.30-11.00

Biomarkers for diagnosis, risk stratification and guidance of therapy in pulmonary embolism
M. Lankeit (Germany)

Free communications

11.00-11.15

Use and interpretation of troponin analysis in Norwegian laboratories
K.M. Aakre (Norway)

11.15-11.30

Usefulness of a new highly sensitive troponin I assay in predicting mortality in unselected negative-troponin patients as measured by imprecise troponin I assays
E. Fernandez (Spain)

Kindly offered by



Hall GB1

CLINICAL TOXICOLOGY

Chair: R. Pacifici (Italy)

9.30-10.00

Frontiers on clinical toxicology
R. Pacifici (Italy)

10.00-10.30

Non conventional biological matrices in clinical pharmacotoxicology
S. Pichini (Italy)

10.30-11.00

New analytical frontiers in clinical toxicology: the...omics come into play
J. Segura (Spain)

Free communications

11.00-11.15

Measurement of barbiturates and Midazolam for use in brain-death diagnostic by HPLC and immunoassays
R.W. Schmid (Austria)

11.15-11.30

Lead poisoning through traditional medicines
T. Venkatesh (India)

13

June

8

Monday

Hall GB2

HOW TO DEFINE AND DETERMINE REFERENCE INTERVALS AND DECISION LIMITS IN LABORATORY MEDICINE
(IFCC Scientific Division)


Chair: M. Panteghini (Italy)

9.30-10.00

The theory of reference values in the new millenium
JC. Boyd (USA)

10.00-10.30

Defining abnormal biomarker values: reference limits, decision limits, thresholds for risk
J. Henry (France)

10.30-11.00

Worldwide useful reference intervals in clinical enzymology: results from a multicentre study
F. Ceriotti (Italy)

11.00-11.30

Experimental factors influencing selection of decision limits for cardiac troponin
M. Panteghini (Italy)

Hall BRUSSEL

BIOBANKING CONCEPTS - NEED FOR AN INTEGRATED EUROPEAN SOLUTION

Chair: G. Schmitz (Germany)

9.30-10.00

Biobanking and pre-analytical issues related to the collection of biological fluids for proteomics biomarker discovery programs in the neurodegenerative field
S. Lehmann (France)

10.00-10.30

The Swedish biobank model and the biobank organization at Karolinska Institute
A. Beskow (Sweden)

10.30-11.00

Harmonisation of European biobanking initiatives
K. Zatloukal (Austria)

Free communications**11.00-11.15**

Helicobacter pylori Epiya-C motifs are main determinants of intestinal metaplasia and gastric mucosa atrophy
C.F. Zambon (Italy)

11.15-11.30

Prognostic significance of DNA methylation markers in tissues and corresponding cell-free circulating DNA in plasma of NSCLC patients
E. Lianidou (Greece)

Hall STRASSBURG

VITAMIN D METABOLITES IN CANCER, IMMUNOLOGICAL AND CARDIOVASCULAR DISEASES

Chair: H.S. Cross (Austria)

9.30-10.00

Interleukin-8 as a predictive
biomarker for immunoregulation
induced by vitamin D receptor
agonists

L. Adorini (Italy)

10.00-10.30

Vitamin D Metabolites and
cardiovascular disease - novel
evidence for prevention

S. Pilz (Austria)

10.30-11.00

Extrarenal vitamin D metabolism
and cancer prevention

H.S. Cross (Austria)

Free communications

11.00-11.15

Plasma 25-hydroxyvitamin D
suppresses matrix
metalloproteinase 9 in pre-
angioplasty patients on statins

P. Timms (United Kingdom)

11.15-11.30

Gender-dependent 1,25-(OH)₂D₃
accumulation in the proximal colon
enhances apoptosis in female
mice

T. Nittke (Austria)

15
June
8
Monday

12.00 - 13.00**Hall TYROL****LABORATORY DIAGNOSTICS - LESSONS FROM CLINICAL TRIALS AND EPIDEMIOLOGICAL STUDIES****Matthew J. McQueen (Canada)***Professor, Pathology and Molecular Medicine*

Dr. McQueen received his medical and Ph.D. degrees from the University of Glasgow, Scotland, and clinical and laboratory training at the Royal Infirmary and its Department of Pathological Biochemistry. He is a Professor in the Department of Pathology and Molecular Medicine at McMaster University, Director of the Lipid Research Clinic and Director of the Clinical Trials and Clinical Research Laboratory. He is a Fellow of the Royal College of Physicians of Canada and a founding Fellow of the Canadian Academy of Clinical Biochemistry. He has served on the Editorial Boards of scientific journals and has been a reviewer for many clinical and scientific publications. His research interests are in the prediction and prevention of cardiovascular disease and diabetes. He has been an invited speaker in 45 countries and is an author of more than 140 scientific papers. Dr. McQueen has been President of the International Federation of Clinical Chemistry and Laboratory Medicine. He has also been President of the Canadian Society of Clinical Chemists and Chairman of the Board of the Canadian Academy of Clinical Biochemistry.

Hall TYROL

**FROM STEM CELLS TO
CARDIOVASCULAR
THERAPY**

Chair: M. Ruel (Canada)

14.30-15.00

Cardiac cell therapy: Current efficacy and monitoring Issues
M. Ruel (Canada)

15.00-15.30

Tissue engineering approaches to enhancing or enacting cell therapy
O. Schussler (France)

15.30-16.00

Cell therapy for restoration cardiac function, so near, so far?
R.K. Li (Canada)

Hall GB1

**SCREENING AND
IDENTIFYING SMALL TO
LARGE MOLECULES IN
CLINICAL CHEMISTRY BY
MASS SPECTROMETRY**

Chair: D. Hochstrasser (Switzerland)

14.30-15.00

Screening, identifying and quantifying small molecules by hyphenated mass spectrometry in toxicology & drug monitoring
H. Maurer (Germany)

15.00-15.30

Chemo-proteomics & protein complexes
G. Sperti-Furga (Austria)

15.30-16.00

Clinical chemistry, biomarkers & proteomics
D. Hochstrasser (Switzerland)

Free communications

16.00-16.15

A key step in HPLC-MS/MS assay validation: assessment of co-medication and matrix interference influence on ion yields
C. Seger (Austria)

16.15-16.30

Identification of microorganisms using mass spectrometry: Introducing the maldi biotyper
R.C. Krieg (Germany)

17
@
June
8
Monday

18
June
8
Monday**Hall GB2****QUALITY MANAGEMENT IN
EUROPE - IMPLEMENTATION
OF ISO-15189****(European Federation of
Clinical Chemistry and
Laboratory Medicine)**

symposium

Chair: W. Huisman (The Netherlands)

14.30-15.10ISO15189: not just
bureaucracy but a logical
system for implementation of a
quality system in the medical
laboratory*D. Burnett* (United Kingdom)**15.10-15.50**Safety management is an
inherent aspect of the
ISO15189 quality system*M. Plebani* (Italy)**15.50-16.30**Implementation of ISO15189 in
European countries - present
status and some items for
harmonisation in the near
future*W. Huisman* (The Netherlands)

Room AALBORG

8.00-9.30 Closed Meeting
IFCC Working Group
on eNewsletter

Chairs: Dr. E. Delvin, Dr. E. Jacobs

Room NEW ORLEANS

8.30-10.00 Closed Meeting
CCLM Steering Committee

Room FREIBURG 1

9.00-12.00 Closed Meeting
IFCC Committee on Molecular
Diagnostics

Chair: Dr. F. Rousseau

Room FREIBURG 2

9.00-12.30 Closed Meeting
IFCC Working Group on HbA1c
Chair: Dr. G. John

Room GRENOBLE

9.00-17.30 Open Meeting
IFCC Committee on Reference
Systems of Enzymes
Chair: Prof. G. Schumann

Room AALBORG

9.30-12.30 Closed Meeting
EC4 Working Group

Room NEW ORLEANS

10.00-11.30 Closed Meeting
EFCC Committee on Education
and Training

Chairs: Prof. V. Blaton, Prof. E.
Topic

Room FREIBURG 2

12.30-17.30 Closed Meeting
IFCC Working Group on HbA2
Chair: Dr. A. Mosca

Room AALBORG

13.00-14.30 Closed Meeting
IFCC Biomedical Journal Editors
and Publisher
Chairs: Dr. E. Delvin, Dr. E. Jacobs

Room FREIBURG 1

14.30-16.30 Closed Meeting
IFCC Corporate Members
Chair: Dr. T. Brinkmann

Room AALBORG

15.00-17.30 Closed Meeting
IFCC Committee on Clinical
Molecular Biology Curriculum
Chair: Prof. M. Neumaier

19
@
June
8
Monday

Hall BRUSSEL
13.00-14.00

**USE OF BIOMARKERS IN
 HEART DISEASE**



Chair: J. Shih (USA)

13.00-13.30
 The MORGAM Study - multiple
 biomarkers for risk stratification
S. Blankenberg (Germany)

13.30-14.00
 Biomarkers in heart failure and
 valvular heart disease
C. Müller (Switzerland)

Hall STRASSBURG
13.00-14.00

**THE CONCEPT OF
 ANALYTICAL TRACEABILITY
 AND THE STANDARDISATION
 OF HbA1c**



Chair: G. John (United Kingdom)

13.00-13.10
 The concept of analytical
 standardisation
G. John (United Kingdom)

13.10-13.45
 Achieving international
 standardisation of HbA1c
C. Weykamp (The Netherlands)

13.45-13.50
 HbA1c standardisation at a
 national level: the current
 situation
G. John (United Kingdom)

13.50-14.00
 Discussion

Hall GB2
13.15-14.15

THE POWER OF NETWORKING



Chair: *R. Hinzmann* (Germany)

13:15-13.45

"Health 2.0": using the internet for networking with medical experts

B. Bergh (Germany)

13:45-14.15

Bringing experts together: network practice in haematology

K. Dombrowski, G. Schreck (Germany)

Hall BRUSSEL
14.15-15.15

"PERSONALISED HEALTH CARE - WHAT IT TAKES TO BE A LEADER"



How Pharma and Diagnostics can work together to provide better, safer and more efficacious treatments

S. Schwan (Switzerland)

21
June
8
Monday

22

 June
8
Monday

INDUSTRY-SPONSORED WORKSHOPS

Hall STRASSBURG
14.15-15.15

**INTEGRATED DIAGNOSTICS
WHAT DO YOU THINK THE
NEXT GENERATION OF
HEALTHCARE WILL LOOK
LIKE?**

SIEMENS

Chair: L. LaSalvia (USA)

14.15-14.25

Brief integrated diagnostics
introduction and overview
L. LaSalvia (USA)

14.25-14.45

Liver fibrosis and its diagnosis
W. Jimenez (Spain)

14.45-15.05

Personalized medicine and
integrated diagnostics
P. Lambin (The Netherlands)

15.05-15.15

Q&A
L. LaSalvia (USA)

Hall BRUSSEL
15.30-16.30

**BIOCHIPS CAN
SAVE LIVES:
CARDIOVASCULAR DISEASE**



Chair P. Twomey
(United Kingdom)

15.30-16.00

Multi-marker approach with the
use of biochip cardiac array
technology for early diagnosis in
patients with acute coronary
syndromes
G. O. Sypniewska (Poland)

16.00-16.30

Early diagnosis of acute coronary
syndrome: are we measuring the
right markers?
M. Myers (United Kingdom)

Hall STRASSBURG
15.30-16.30

**THE FUTURE AND
IMPORTANCE OF
SOLUTION BUSINESS**



Chair: *H. Vitzthum* (Germany)

15.30-15.55

Session I: case study: laboratory
turnkey solution at Ospedale dell'
Angelo in Mestre, Italy
M. Gion (Italy)

16.00-16.30

Session II: the "Lean" concept -
manage your productivity
D. Streicher (Germany)

Hall BRUSSEL
16.45-17.45

**WHAT IS NEW ON CARDIAC
TROPONIN?**



Chair: *M. Panteghini* (Italy)

16.45-17.00

Place of troponin in the new
ESC/ACC AMI redefinition
M. Panteghini (Italy)

17.00-17.15

TnT-hs analytical performances
P. Venge (Sweden)

17.15-17.30

TnT-hs added clinical value
E. Giannitsis (Germany)

17.30-17.45

Questions and Closing

23
June
8
Monday

24

June

8

Monday

Hall STRASSBURG
16.45-17.45

**DIAGNOSTIC
PERFORMANCE AND
CLINICAL VALUE OF
HOLOTRANSCOBALAMIN,
MEASURED BY THE
AXSYM ACTIVE-B12 ASSAY,
FOR VITAMIN B12 STATUS**



Chair: *J. Scott* (Ireland)

16.45-17.05

The clinical performance and robustness of holotranscobalamin measurement in assessing vitamin B12 status
J. Scott (Ireland)

17.05-17.25

Running the AxSYM active B12 assay in the reference laboratory: Melbourne pathology experience
K. Sikaris (Australia)

17.25-17.45

Towards improved diagnostic decision making: cobalamin and folate deficiency
O. Stanger (Austria)



Quality Control

The most comprehensive menu of quality control products and services

- Over 300 innovative control products
- Unity™ QC Data Management Solutions
- The most widely used Interlaboratory Program
- Superior customer support

Also inquire about our products for Diabetes Monitoring, Autoimmune Testing, Genetic Disorders, Immunohematology, Clinical Microbiology, Virology, Special Chemistry and Toxicology - **Improving lives with every test**

www.bio-rad.com/diagnostics



Hall TYROL

**DIABETES MELLITUS,
 ATHEROSCLEROSIS,
 RENAL FAILURE - "POST
 TRANSLATIONAL
 PATHOLOGIES"**

Chair: P. Gillery (France)

9.30-10.00

Glycation and glycoxydation of proteins in diabetes mellitus, atherosclerosis and renal insufficiency
A. Lapolla (Italy)

10.00-10.30

Carbamylation of proteins in renal insufficiency and atherosclerosis
P. Gillery (France)

10.30-11.00

Amadoriases, enzymes of deglycation and protein reparation
E. Van Schaftingen (Belgium)

Hall GB1

**PEDIATRIC REFERENCE
 RANGES
 (American Association for
 Clinical Chemistry)**

AACC *symposium*

Chair: M. Bennett (USA)

9.30-10.10

Meeting the challenge of pediatric reference intervals: concept to current status
P. Jones (USA)

10.10-10.50

CALIPER: A Canadian initiative on pediatric reference intervals
V. Grey (Canada)

10.50-11.30

The United States national children's study
M. Bennett (USA)

Hall GB2

**STANDARDIZATION
ACTIVITIES IN
ENDOCRINOLOGY
(IFCC Scientific Division)**



Chair: I. Young (United Kingdom)

9.30-10.00

Benefits of insulin assay
standardization
P. Clark (United Kingdom)

10.00-10.30

Growth hormone - the need for
standardization
M. Bidlingmaier (Germany)

10.30-11.00

Human chorionic gonadotropin;
impact of standardization on
clinical practice
C. Sturgeon (United Kingdom)

11.00-11.30

Development of reference systems
for serum total and free thyroxine
measurements
L. Thienpont (Belgium)

Kindly offered by



Hall BRUSSEL

**PROTEOMICS AND HUMAN
DISEASE**

Chair: H. Meyer (Germany)

9.30-10.00

Creation of a human protein atlas
to study human diseases
C. Kampf (Sweden)

10.00-10.30

Characterisation of the
autoimmune antibody repertoire of
Parkinson's disease patients by
systematic screening of protein
arrays
H. Meyer (Germany)

10.30-11.00

Proteomic strategies in breast
cancer research
J. Celis (Denmark)

Free communications

11.00-11.15

Proteomics to study phorbol-
myristate-acetate (pma) effects on
endothelial cells
B. Baudin (France)

11.15-11.30

Proteomic profiling to reveal
molecular mechanisms underlying
thrombosis in acute myocardial
infarction
M. Kubicek (Austria)

27
June
9
Tuesday

28
June
9
Tuesday**Hall STRASSBURG****TRANSLATIONAL
RESEARCH:
RE-ENGINEERING THE
LABORATORY MEDICINE
ENTERPRISE**

Chair: B. Gouget (France)

9.30-10.00Mapping translational research in
personalized laboratory medicine
J.C. Forest (Canada)**10.00-10.30**Implementing a EU translational
research in a biopark network
environment
G. Charpentier, F. Russo-Marie
(France)**10.30-11.00**Creating a new culture and
organization for oncology around
translational research
J.M. Bidart (France)

12.00 - 13.00

Hall TYROL

GLYCOMICS – STATE OF THE ART

Rudolf Tauber (Germany)

Professor of Clinical Chemistry and Pathobiochemistry



1972-1979 Study of medicine at University of Freiburg, Germany. 1980 Thesis M.D., Department of Biochemistry (Prof. Dr. W. Reutter), University of Freiburg, Germany. 1980-1984 Postdoc at Institute for Molecular Biology and Biochemistry (Prof. Dr. W. Reutter), Freie Universität Berlin, Germany. 1984-1987 Research fellow at the Department of Gastroenterology and Hepatology (Prof. Dr. W. Gerok), University of Freiburg, Germany. 1987-1997 Professor of Clinical Biochemistry, Institute of Clinical

Chemistry and Biochemistry (Prof. Dr. E. Köttgen), Virchow-Klinikum, Medical Faculty of the Humboldt-Universität zu Berlin, Germany. 1997 - hitherto Professor of Clinical Chemistry and Pathobiochemistry, Universitätsklinikum Benjamin Franklin, Freie Universität Berlin, since 2003 Charité - Universitätsmedizin Berlin. Since 2006 director of the Central Institute of Laboratory Medicine and Pathobiochemistry of the Charité - Universitätsmedizin Berlin. 1997 - 2002 Member of the Scientific Division of the International Federation of Clinical Chemistry. Areas of research: signal transduction, cell adhesion in inflammation and oncology, glycomics.

29
June
9
Tuesday

Hall TYROL

**PHARMACOGENETICS IN
LABORATORY MEDICINE:
FROM BENCH TO BEDSIDE**

Chair: M. Plebani (Italy)

14.30-15.00

Pharmacogenetics of P 450
genotypes
M. Plebani (Italy)

15.00-15.30

Pharmacogenetics testing in
anticoagulation therapy
R. Valdes (USA)

15.30-16.00

Pharmacogenetics of azathioprine
and 6-mercaptopurine
R. Van Schaik (The Netherlands)


Free communications**16.00-16.15**

Effect of abc drug transporter
genotypes on antiepileptic drug
disposition
N. Bozina (Croatia)

16.15-16.30

Vkorc1 and cyp2c9
pharmacogenetics: relevance in
warfarin maintenance dosing
prediction.
C.F. Zambon (Italy)

Hall GB1

**UPDATE ON
CARDIOVASCULAR
MARKERS
(European Federation of
Clinical Chemistry and
Laboratory Medicine)**


Chair: K. Pulkki (Finland)

14.30-15.00

Do we need markers for troponin-
negative chest pain patients?
J. Mair (Austria)

15.00-15.30

High-sensitive troponin in renal
failure and in severe exercise
*M. Van Dieijen-Visser
(The Netherlands)*

15.30-16.00

What are the decision limits for
natriuretic peptides?
P. Collinson (United Kingdom)

16.00-16.30

Survey on use of cardiac markers
(CAMARGUE)
K. Pulkki (Finland)

Hall GB2

**CLINICAL CASES -
ENDOCRINOLOGY**

Conductor:

A. Griesmacher (Austria)

INTERACTIVE



A voting system will be provided.
This session will allow delegates
to interact with the speaker and
make the session an active one!

31
June
9
Tuesday

32

 June
 9
 Tuesday
Room AALBORG

8.30-12.00 Closed Meeting
 CCLM Editorial Board

Room FREIBURG 1

9.00-11.00 Closed Meeting
 EFCC Working Group on
 Creatinine Standardisation
Chair: Prof. J. Delanghe

Room NEW ORLEANS

9.00-12.30 Closed Meeting
 IFCC Committee on Analytical
 Quality
Chair: Dr. K. Sikaris

Room GRENOBLE

10.00-11.30 Closed Meeting
 IFCC-Worldlab-Euromedlab Berlin
 2011 - *meeting with companies*

Room FREIBURG 1

12.00-17.30 Closed Meeting
 IFCC Committee on Reference
 Intervals and Decision Limits
Chair: F. Ceriotti

Room FREIBURG 2

12.00-14.30 Closed Meeting
 EFCC Working Group on Guidelines
Chair: Dr. W. Oosterhuis

Room AALBORG

13.00-14.30 Closed Meeting
 Journal Clinical Biochemistry
Chair: Dr. A. Newman

Room NEW ORLEANS

14.00-17.30 Closed Meeting
 IFCC Committee on Traceability in
 Laboratory Medicine
Chair: Dr. J. Kessler

Room FREIBURG 2

15.00-17.30 Closed Meeting
 IFCC Working Group on
 Standardisation of Human
 Chorionic Gonadotropin
Chair: Dr. C. Sturgeon

Room AALBORG

15.00-17.30 Closed Meeting
 IFCC-Worldlab-Euromedlab Berlin
 2011 - *International Scientific
 Committee*

Hall BRUSSEL
13.00-14.00

DIRECTING THE SPOTLIGHT ON RENAL DISEASE



Chair: L. Lennartz (Germany)

13.00-13.30

Swedish guidelines for estimating
glomerular filtration rate (GFR)
and results of the ARCHITECT
Cystatin C assay validation
A. Larsson (Sweden)

13.00-14.00

Urine N-Gal - a novel marker for
Acute Kidney Injury (AKI)
C. Ronco (Italy)

Hall STRASSBURG
13.00-14.00

AUTOMATION SOLUTIONS FOR LABORATORIES IN HOSPITAL NETWORKS



Chair: P. Simonsson (Sweden)

13.00-13.20

Flexible solutions for evolving
laboratory needs
A. Piening (Switzerland)

13.20-13.40

Laboratory consolidation of a
network of five regional hospitals
M. Balerna (Switzerland)

13.40-14.00

Automation at Southampton:
benefits and aspirations
J. Wood (United Kingdom)

33
June
9
Tuesday

34

 June
9
Tuesday

Hall GB2
13.15-14.15

BEYOND BLOOD



Chair: R. Hinzmann (Germany)

13:15-13.45

Canalising the data flood: the XE-5000 case manager combines laboratory data with clinical knowledge
F. Forstreuter (Germany)

13:45-14.15

Reliable and fast: standardised analysis of CSF and other body fluids
J. Dittmann (Germany)

Hall BRUSSEL
14.15-15.15

COMPLEMENTARY ROLE OF SEROLOGY AND NAT IN THE DIAGNOSIS OF VIRAL HEPATITIS



Chair: C. Galli (Italy)

14.15-14.45

Quantitative HBsAg - independent parameter to determine response to therapy in patients with chronic HBV infection?
M. Brunetto (Italy)

14.45-15.15

Screening for HCV in a high risk population - benefits of HCV antigen testing
E. Daghofer (Austria)

Hall STRASSBURG
14.15-15.15

**NEW DEVELOPMENTS IN
PROSTATE CANCER
MANAGEMENT**



Chair: T. Brinkmann (Switzerland)

14.15-14.45

Clinical dilemmas in prostate cancer diagnostics and treatment
B. Tombal (Belgium)

14.45-15.00

Clinical utility of [-2]proPSA: A novel marker intended for use as an aid in distinguishing prostate cancer from benign prostatic conditions
C. Weinzierl (USA)

Hall BRUSSEL
15.30-16.30

**ADVANCES IN CLINICAL
DIAGNOSTICS BY LC-MS/MS-
NOVEL DIAGNOSTIC KITS &
QUALITY CONTROLS AND
THEIR VALUE FOR ROUTINE
CLINICAL LABORATORIES**



Chair: F. Kühlwein (Germany)

15.30-16.00

Analytical aspects in therapeutic drug monitoring of psychoactive drugs
S. Bauer (Germany)

16.00-16.30

Latest developments in clinical diagnostics with tandem mass spectrometry - novel diagnostic kits & quality controls and their value for clinical laboratories
F. Kühlwein (Germany)

35
June
9
Tuesday

Hall STRASSBURG
15.30-16.30

**THE CLINICAL VALUE OF
 SERUM HER-2/neu IN
 BREAST CANCER PATIENTS
 - AN UPDATE**

SIEMENS

Chair: P.E.C. Sibley (United Kingdom)

15.30-16.00

Serum HER-2/neu as a tumor marker in breast cancer patients
P. Stieber (Germany)

16.00-16.30

The clinical relevance of serum HER-2/neu in the management of metastatic breast cancer patient management
V. Heinemann (Germany)

Hall BRUSSEL
16.45-17.45

**THE URINARY SEDIMENT:
 AN UPDATE**

A.MENARINI
 diagnostics

Chair: G.B. Fogazzi (Italy)

16.45-17.05

Some particles of urine sediment and their clinical significance
Z. Zaman (Belgium)

17.05-17.25

Latest development of sediMAX technology
G. Bayer (Hungary)

17.25-17.45

Comparison between phase contrast microscopy and sediMAX
G.B. Fogazzi (Italy)

Hall STRASSBURG
16.45-17.45

**ROCHE'S NEW SOLUTION
FOR HIGH VOLUME
LABORATORIES.
cobas® 8000 MODULAR
ANALYZER: A NEW
DIMENSION OF EFFICIENCY
AND PRODUCTIVITY**



16.45- 17.05

Introduction of the new high throughput serum work area solution

S. Bieger (Switzerland)

17.05-17.20

First experience with cobas 8000 modular analyzer in a university hospital laboratory: Evaluation of the overall performance

A. von Eckardstein (Switzerland)

17.20- 17.35

From modular analytics to cobas 8000 modular analyzer: Workflow efficiency with a focus on speed and STAT handling

H.J. Roth (Germany)

17.35-17.45

Questions and Closing

37
Tuesday 9 June

Hall TYROL

**FRONTIERS IN MOLECULAR
HAEMATO-ONCOLOGY**

Chair: A. Huber (Switzerland)

9.30-10.00

 Molecular pathogenesis of the
myeloproliferative disorders
A.R. Green (United Kingdom)

10.00-10.30

 Chronic myeloid leukemia (CML):
molecular monitoring in clinical
practice
G. Baerlocher (Switzerland)

10.30-11.00

 Novel molecular approaches in
detecting thalassemic syndromes
A. Huber (Switzerland)

Free communications
11.00-11.15

 Identification of Oncostatin M as a
KIT D816V-dependent cytokine in
neoplastic mast cells
G. Hoermann (Austria)

11.15-11.30

 Rapid immunoprofile in new
lymphocytosis cases using a
routine hematology analyzer: a
multicenter study
J.J.M.L. Hoffmann (Germany)

Hall GB1

**GENOMIC INSTABILITY
SYNDROME**

Chair: Y Shiloh (Israel)

9.30-10.00

 DNA damage repair and the choice
between cancer and aging
J.H. Hoeijmakers (The
Netherlands)

10.00-10.30

 Human premature aging proteins
participate in DNA repair
V. Bohr (USA)

10.30-11.00

 The ATM-Mediated DDR: A bridge
between Lab and Clinic
Y. Shiloh (Israel)

Hall GB2

**EVIDENCE-BASED
EVALUATION OF NEW
SPECIALISED TESTS AND
THEIR COST-
EFFECTIVENESS
(IFCC Education &
Management Division)**



Chair: G. Rothe (Germany)

9.30-10.00

Evidence-based evaluation of new diagnostic interventions
R.A. Horvath (Hungary)

10.00-10.30

Biomarkers in acute coronary syndromes and heart failure: Bargin or Budget Breaker?
R.H. Christenson (USA)

10.30-11.00

Flow cytometric characterization of haematological malignancies and immunodeficiency
G. Rothe (Germany)

11.00-11.30

Genotyping in common metabolic diseases
J.B. Whitfield (Australia)

Hall BRUSSEL

**OBESITIES, DIABETES TYPE
II AND METABOLIC
SYNDROME - NEW CLINICAL
AND DIAGNOSTIC WAYS**

Chair: V. Blaton (Belgium)

9.30-10.00

Inflammatory markers in management of the metabolic syndrome
M. Langlois (Belgium)

10.00-10.30

Macrophage polarization in cardio metabolic disease: control by nuclear receptors
A. Tailleux (France)

10.30-11.00

Increasing high-density lipoprotein cholesterol to prevent cardiovascular disease
J. Kastelein (The Netherlands)

Free communications

11.00-11.15

Inflammation markers in patients with cardiovascular disease and metabolic syndrome
I. Korita (Belgium)

11.15-11.30

Relationship of exhaled nitric oxide concentration to biochemical risk factors in IHD patients
L. Salonen (Finland)

Kindly offered by



39
Wednesday 10 June

Hall STRASSBURG**MODERN CONCEPTS IN
EXTERNAL QUALITY
ASSURANCE**

Chair: R. Bais (Australia)

9.30-10.00

Using external quality assurance to measure the complete laboratory quality system

R. Bais (Australia)

10.00-10.30

External quality assessment in genetic testing: lessons learned and future challenges

H. Dequeker (Belgium)

10.30-11.00

Quality indicators of continuous quality improvement in clinical laboratories

E. Topic (Croatia)

Free communications**11.00-11.15**

External quality assessment of urinary steroid profile analyses

I.J. Phillips (The Netherlands)

11.15-11.30

Outpatient laboratory test report delivery success rate: indicator of the quality of patient care

A.M. Simundic (Croatia)

12.00 - 13.00

Hall TYROL

THE STRESS RESPONSE AND INTRACELLULAR SIGNALLING

Oren Zinder (Israel)

*Professor of Laboratory Medicine at the Technion Faculty of
Medicine*



Professor Oren Zinder was born in Israel in 1940, and received his academic degrees from the Hebrew University in Jerusalem. Following four years at the National Institutes of Health in the USA, in 1975 he was appointed a member of the Department of Clinical Biochemistry at the Rambam Medical Center in Haifa, Israel. In 1978 he was appointed the Director of the Department, and in 1982 established and headed of the Division of Laboratory Medicine at the Rambam tertiary-care, academic, Medical Center in Haifa, which he directed until 2005. He is Professor of Laboratory

Medicine at the Technion Faculty of Medicine in Israel, and established there the first academic programme in Laboratory Medicine in Israel for both undergraduate and post-graduate degrees. This is a joint programme between the Faculty of Biology and the Faculty of Medicine, and the students benefit from the exposure to both basic and clinical sciences. Prof. Zinder is involved in research as well as teaching, and has been a visiting scientist and visiting professor at a number of universities in the USA, Australia, Canada, and Norway. He has been a consultant to the Mexican, Chinese (Beijing), and Thailand, Ministries of Health, and in addition he also consulted for the WHO. Professor Zinder served on the Executive Board of the International Federation of Clinical Chemistry and Laboratory Medicine for six years and as its Secretary-General between the years 1993-1996. In the last ten years, Professor Zinder has been heavily involved in the development of clinical instrumentation and devices. He was the recipient of the AACC Award for Education, and the IFCC Award for Service to the Profession of Clinical Chemistry and Laboratory Medicine.. Professor Zinder has published in both basic sciences and in clinical chemistry and has over 150 professional papers, including two books which he has edited.

41
Wednesday 10 June

Hall TYROL

NEW BIOLOGICAL MARKERS IN NEUROLOGICAL DISORDERS: PRESENCE & FUTURE

Chair: T. Berger (Austria)

14.30-15.00

Emergence of antibodies as diagnostic and prognostic biomarkers in multiple sclerosis
T. Berger (Austria)

15.00-15.30

Onconeural antibodies in paraneoplastic neurological syndromes
F. Graus (Spain)

15.30-16.00

Biomarkers for improving diagnostic and prognostic accuracy in neurodegenerative central nervous system disease
A. Petzold (United Kingdom)

Free communications

16.00-16.15

Observations on the use of amyloid β (1-42) ($a\beta$ 42), tau and phosphorylated tau (ptau) as cerebrospinal fluid biomarkers for Alzheimer's disease in clinical research
M.A. Blankenstein (The Netherlands)

16.15-17.00

Plasma 24s-hydroxycholesterol and caudate atrophy in Huntington's disease
L. Valerio (Italy)

Hall GB1

DIAGNOSIS AND MANAGEMENT OF BONE AND JOINT DISEASES

Chair: G. Sypniewska (Poland)

Co-Chair: E. Delvin (Canada)

14.30-15.00

Evaluation of individual fracture risk
R.S. Lorenc (Poland)

15.00-15.30

Novel biochemical markers of bone remodeling in assessment of bone metabolic diseases
K.K. Ivaska (Finland)

15.30-16.00

Markers of cartilage metabolism in joint diseases
M.A. Karsdal (Denmark)

Free communications

16.00-16.15

Novel estrogen-regulated gene identified in mouse with importance for the regulation of bone mineral density in humans
F. Rousseau (Canada)

16.15-16.30

Validation and accuracy profiles of the liaison bap-ostase (DiaSorin), a new method for the determination of bone alkaline phosphatase
E. Cavalier (Belgium)

Hall GB2

CLINICAL CASES - AUTOIMMUNE DISORDERS- ALLERGOLOGY

Conductor:

M. Herold (Austria)

INTERACTIVE



A voting system will be provided.
This session will allow delegates
to interact with the speaker and
make the session an active one!

Kindly offered by

Phadia

43
Wednesday 10 June

Room GRENOBLE**8.30-11.30 Closed Meeting**IFCC Committee on
Plasma ProteinsChair: Prof. G. Merlini**Room FREIBURG 1****9.00-11.00 Closed Meeting**

IFCC Bergmeyer Conference

Chairs: Prof. M. Panteghini,
Dr. F. Baumann**Room NEW ORLEANS****9.00-13.00 Closed Meeting**IFCC Working Group on
Standardisation of Pregnancy-
Associated Protein AChair: Prof. K. Petterson**Room AALBORG****9.00-13.00 Closed Meeting**

EFCC Register Commission

Chair: Dr. J. Mc Murray**Room FREIBURG 2****9.30-16.00 Closed Meeting**IFCC Integrated Working Group on
PharmacogeneticsChair: Dr. R. Van Schaik**Room FREIBURG 1****12.00-17.30 Closed Meeting**IFCC Committee on Molecular
DiagnosticsChair: Dr. F. Rousseau**Room GRENOBLE****14.00-17.30 Closed Meeting**

EFCC General Assembly

Room NEW ORLEANS**14.00-17.30 Closed Meeting**IFCC Working Group on Ibero -
American Nomenclature and
Translations (RIA)Chair: Prof. M. Blanes Gonzales**Room AALBORG****14.00-17.30 Closed Meeting**IFCC Working Group on
Standardisation of CystatinChair: Dr. A. Grubb

Hall BRUSSEL
13.00-14.00

**PREVENTION AND EARLY
DETECTION OF
GYNECOLOGICAL CANCER**



Chair: A. Vockel (Germany)

13.00-13.30

The combination of CA125 and HE4 in the diagnosis of ovarian cancer

P. Stieber (Germany)

13.30-14.00

The role of Human Papilloma Virus (HPV) in the development of cervical cancer

M. Poljak (Slovenia)

Hall STRASSBURG
13.00-14.00

**CURRENT AND FUTURE
PERSPECTIVES WITH
CARDIAC BIOMARKERS**



Chair: T. Brinkmann (Switzerland)

13.00-13.30

Clinical Performance of Contemporary cTnI Assays - Access® AccuTnI®, Architect cTnI, Centaur TnI-Ultra and POC cTnI

P. Venge (Sweden)

13.30-14.00

AccuTnI®, hs-cTnI, and c-PAPP-A: Three cardiac biomarkers fulfilling three important roles in an Acute Coronary Syndrome population

P. Kavsak (Canada)

45
Wednesday 10 June

Hall GB2
13.15-14.15

**MANAGING URINARY
TRACT INFECTION (UTI) -
STILL A CHALLENGE?**



Chair: R. Hinzmann (Germany)

13:15-13.45

Pitfalls, problems and unsolved puzzles in urinary tract infection management

H. von Wulffen (Germany)

13:45-14.15

Swift, sensitive, Sysmex: Automated counting of bacteria and Leukocytes

S. Jäkel, O. Hauss (Germany)

Hall BRUSSEL
14.15-15.15

**ADVANCES IN
REPRODUCTIVE
ENDOCRINOLOGY AND
HIGH-RISK PREGNANCY
TESTING**



Chair: T. Brinkmann (Switzerland)

14.15-14.35

Comparison of a newly developed ultrasensitive estradiol immunoassay with the ID-GCMS reference method

S. Faye (Switzerland)

14.35-14.55

Anti-Müllerian hormone: A new ovarian growth factor of emerging clinical significance

T. Katzorke (Germany)

14.55-15.15

New markers for diagnosis of preeclampsia

V. Tsatsaris (France)

Hall STRASSBURG
14.15-15.15

BIOCHIPS TO ADVANCE RESEARCH



Chair: M. Corsi (Italy)

14.15-14.45

Studies with the cytokine & growth factors and cell adhesion molecule arrays using the Randox evidence investigator
H. van Pelt (The Netherlands)

14.45-15.15

Implementing the Randox investigator drugs of abuse array in routine biochemistry
I. Godber (United Kingdom)

Hall BRUSSEL
15.30-16.30

RECENT ADVANCES IN THE MANAGEMENT OF FREE LIGHT CHAIN DISEASE



Chair: J. Drach (Austria)

15:30 - 15:32

Introduction
J. Drach (Austria)

15:32 - 15:47

Application and clinical significance of serum free light chain testing
J. Drach (Austria)

15:50 - 16:05

The new international myeloma working group myeloma guidelines and how they impact the laboratory
J. Katzmann (USA)

16:10 - 16:25

Treatment of acute renal failure secondary to multiple myeloma with chemotherapy and extended high cut-off hemodialysis
P. Cockwell (United Kingdom)

16:28 - 16:30

Conclusion and close
J. Drach (Austria)

47
Wednesday 10 June

48

Wednesday 10 June

Hall STRASSBURG
15.30-16.30

**THE APPROPRIATE
APPLICATION OF LEAN**

Ortho Clinical Diagnostics
a Johnson & Johnson company

Chair: H. Baum (Germany)

15.30 - 16.00

ValuMetrix® & the lean principles
applied to hospital laboratories
P. M. Button (United Kingdom)

16.00-16.30

A customer's perspective on lean
L. Vallier (USA)

Hall BRUSSEL
16.45-17.45

**HAEMOLYSIS: CAUSES,
AFFECTS, PREVALENCE,
MEASUREMENT &
SOLUTIONS IN PATHOLOGY**


BD
 Helping all people
live healthy lives

Chair: V. Palicka (Czech Republic)

16.45-17.10

Haemolysis: Causes, effects &
prevalence
G. Lippi (Italy)

17.10-17.30

Haemolysis: Measurement &
solutions
N. Blanckaert (Belgium)

17.30-17.45

Discussion & Questions

Hall STRASSBURG
16.45-17.45

**ABX PENTRA 400®
EVALUATION FOR
THERAPEUTIC DRUG
MONITORING AND DRUG
ABUSE TESTING**



16:45-17:00

HORIBA Medical Corporate
presentation

17:00-17:30

Evaluation of the ABX Pentra
400® for drugs of abuse test and
therapeutic drug monitoring:
Market analysis

The ABX Pentra 400®

The environment

Comparison between ABX Pentra
400®, Cobas Mira® and
Siemens Dimension Xpand®

The evaluation

M. Galliot-Guilley (Paris)

17:30-17:45

Questions/Answers

49
Wednesday 10 June

Hall TYROL

**BIOLOGY AND
DIAGNOSTICS OF RENAL
FUNCTION**

Chair: A. Grubb (Sweden)

9.30-10.00

Replacing invasive with non-invasive methods for estimating renal function

A. Grubb (Sweden)

10.00-10.30

Cystatin C a new significant marker for the future risk!

L.O. Hansson (Sweden)

10.30-11.00

Urine protein pattern: An important tool for diagnosing kidney disease

W. Hofmann (Germany)

Free communications
11.00-11.15

Development of an affordable dye-stained microalbuminuria screening test

P.L. Tugirimana (Belgium)

11.15-11.30

The significance of cystatin C and its derived EGFR in patients undergoing cardiac surgery

JD. McNeilly (United Kingdom)

Kindly offered by



Hall GB1

AUTOIMMUNE DISEASES

Chair: RL. Humbel (Luxembourg)

9.30-10.00

Autoimmune diseases of the nervous system

RL. Humbel (Luxembourg)

10.00-10.30

Autoantibody detection in 2009

N. Bizzaro (Italy)

10.30-11.00

Autoantibodies in liver diseases

D.P. Bogdanos (United Kingdom)

Free communications
11.00-11.15

Anti-annexin a5 antibodies in primary antiphospholipid syndrome

M. Becarevic (Serbia)

11.15-11.30

Development of novel antibody biomarkers for diagnostic protein biochips - the rheumatoid arthritis case study

A. Lueking (Germany)

Hall GB2

**LABORATORY
PERFORMANCE AND
PATIENT SAFETY
(IFCC Education &
Management Division)**



Chair: M. Plebani (Italy)

9.30-9.54

Laboratory errors and patient safety: an overview
M. Plebani (Italy)

9.54-10.18

Problem solving and risk management in the pre-analytical phase
G. Lippi (Italy)

10.18-10.42

Analytical errors and interferences
O. Sonntag (Germany)

10.42-11.06

Point of care testing (POCT) and medical errors
S. Ehermeyer (USA)

11.06-11.30

Laboratory reporting: a tool for improving quality and patient safety
L. Sciacovelli (Italy)

Kindly offered by



Hall BRUSSEL

**FRONTIERS IN
THERAPEUTIC DRUG
MONITORING
(International Association of
Therapeutic Drug
Monitoring and Clinical
Toxicology)**



Chair: Pierre Marquet (France)

9.30-10.10

Therapeutic drug monitoring - The ever widening scope
D. Holt (United Kingdom)

10.10-10.50

Contemporary therapeutic drug management: Merging drug concentrations, biomarkers, pharmacogenetics and informatics
S. Vinks (USA)

10.50-11.30

Translational research for today and tomorrow's TDM of transplantation drugs.
P. Marquet (France)

51
Thursday 11 June

52

Thursday 11 June

Hall STRASSBURG**POCT: MODELS FOR DELIVERY IN HOSPITALS, GP PRACTICE AND HOME. ENSURE QUALITY AND IMPROVED PATIENT OUTCOME**

Chair: S. Sandberg (Norway)

9.30-10.00

Organizing hospital POCT to ensure quality and improved patient outcomes

*J. Nichols (USA)***10.00-10.30**

Organizing general practitioners' POCT to ensure quality and improved patient outcome

*S. Sandberg (Norway)***10.30-11.00**

A new paradigm for regional community health

*C. Lehmann (USA)****Free communications*****11.00-11.15**

Errors in the transcription of blood glucose results in a hospital POCT setting

P. Carraro (Italy)

12.00 - 13.00

Hall TYROL

THE ENVIRONMENT AND LABORATORY DIAGNOSTICS: NEW OPPORTUNITIES AND NEW DUTIES

Paolo Mocarelli (Italy)

Professor of Clinical Biochemistry at the Medical School, University Milano-Bicocca



Full Professor of Clinical Biochemistry at the Medical School, University Milano-Bicocca, Italy. He has been Director of the postgraduate Specialty School of "Clinical Biochemistry" of the same University Medical School and of the University Department of Laboratory Medicine of the Hospital Desio. Coordinator of the Clinical Laboratory Projects "For monitoring health of the population of the Seveso area", since the dioxin accidental pollution in 1976. Dr. Mocarelli has been visiting professor at the Wistar Institute, Philadelphia, USA and he is collaborating in research on the effects of dioxin on humans with Institutions such as Karolinska (Sweden), National Institute of Health Helsinki (FL), University of Berkeley of Public Health, Berkeley (USA), NIESH (USA) and others. Author of 200 papers, 150 of them in international peer reviewed journals. President (1995) of the Italian Society of Clinical Biochemistry and Clinical Molecular Biology. (SIBioC). Treasurer (1997-2002) of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC). Chairman of the "19th International Congress on Dioxins", September 1999 with the participation of about 1000 experts in this field, that is environmental pollutants and health. Cofounder in 2003 of the Italian Proteomic Association (ItPA) and President (2007-2009).

53
Thursday 11 June

54

Thursday 11 June

Hall TYROL

GENETIC DISORDERS OF
BODY FLUID HOMEOSTASIS

Chair: P. Chiba (Austria),
A. Jabor (Czech Republic)

14.30-14.45

Welcome
P. Chiba (Austria)

14.45-15.00

Introduction - Body fluid
homeostasis: From genotype to
phenotype
A. Jabor (Czech Republic)

15.00-15.30

Modulation of cation-coupled
chloride cotransporter's activity by
WNK kinases
G. Gamba (Mexico)

15.30-16.00

Water channel proteins
(aquaporins and relatives) in
human health and diseases
G. Benga (Romania)

16.00-16.30

Genetic disorders of body fluid
homeostasis
P.K. Schlingmann (Germany)

Hall GB1

GUIDELINES FOR
PHARMACOGENETICS/AN
IFCC INTEGRATED PROJECT

Chair: R. Van Schaik
(The Netherlands)

14.30-14.55

IFCC Pharmacogenetic guidelines:
TPMT and CYP2C9/VKORC1 as
starting examples
R.H.N. Van Schaik (The
Netherlands)

14.55-15.20

Tamoxifen and CYP2D6
H. J. Guchelaar (The Netherlands)

15.20-15.45

Genetics of drug hypersensitivity
M. Pirmohamed (United Kingdom)

15.45-16.10

Pharmacogenetics in
transplantation
P. Marquet (France)

16.10-16.30

General discussion & input from
the audience

Hall GB2

**CLINICAL CASES -
HEMATOLOGY -
HEMOSTASEOLOGY**

Conductor:

I. Schwarzingler (Austria)

A 43 year old patient with fever and
pancytopenia

I. Schwarzingler (Austria)

Unexpected events during an
anticoagulation therapy in a 72 year
old patient

P. Quehenberger (Austria)

INTERACTIVE



A voting system will be provided.
This session will allow delegates
to interact with the speaker and
make the session an active one!

Hall BRUSSEL

BIOSTATISTICS

Chair: A.M. Simundic (Croatia)

14.30-15.00

P Value - fact and controversies
L. Bilic-Zulle (Croatia)

15.00-15.30

Adding to diagnostic accuracy:
developments in test evaluations
P. Bossuyt (The Netherlands)

15.30-16.00

The most common statistical
mistakes in biomedical literature
A.M. Simundic (Croatia)

Free communications

16.00-16.15

Information systems in laboratory
diagnostics should prepare for the
new challenge of emerging
predictive medicine
M. Kapalla (Slovakia)

55
Thursday 11 June

16.45 - 17.30

Hall TYROL

16.45

EUROMEDLAB 2009 President

Mathias M. Müller (Austria)

16.50

Welcome to Berlin

Harald Renz (Germany), Rudolf Tauber (Germany)

Presidents WORLDLAB/EUROMEDLAB Berlin 2011

17.00

Closing remarks

Rita Andrea Horvath (Hungary), Graham Beastall (UK)

EFCC / IFCC Presidents

17.10

This was EUROMEDLAB Innsbruck 2009

Andrea Griesmacher (Austria)

EUROMEDLAB 2009 Executive Manager

17.25

Closing remarks on behalf of the Organising Committee and the Austrian Society of Laboratory Medicine and Clinical Chemistry

Mathias M. Müller (Austria)



Farewell Berlin Party

***See you in Berlin
2011***

Room FREIBURG 1

9.00-17.00 Closed Meeting

IFCC Committee on Molecular
Diagnostics

Chair: Dr. F. Rousseau

Room FREIBURG 2

9.30-14.00 Closed Meeting

IFCC Integrated Working Group
on Pharmacogenetics

Chair: Dr. R. Van Schaik

Room AALBORG

12.00-17.00 Closed Meeting

EFCC Scientific Committee

Chair: Prof. S. Sandberg



57
Thursday 11 June

Hall BRUSSEL
13.00-14.00

**LEARN HOW VITROS®
DIAGNOSTIC SYSTEMS
HELP YOU OPTIMIZE
PRODUCTIVITY IN YOUR
LABORATORY BY USING
OBJECTIVE METRICS**

Ortho Clinical Diagnostics
a *Johnson & Johnson* company

Chair: H. Baum (Germany)

13.00 - 13.30

General introduction of new
decision metrics
P. Button (United Kingdom)

13.30-14.00

A customer's perspective of the
new VITROS® 5600 integrated
System in meeting productivity
goals.
L. Vallier (USA)

Hall STRASSBURG
14.15-15.15

**VITAMIN D: OSTEOPOROSIS
AND BEYOND**



Chair: C. Bieglmayer (Austria)

14.15-14.35

Osteoporosis and vitamin D
measurement
J.C. Souberbielle (France)

14.35-14.55

Vitamin D deficiency and
myocardial dysfunction
S. Pilz (Austria)

14.55-15.15

The optimal circulating level of
25(OH)D and how to achieve it
B. Hollis (USA)



Sharing Visions

Consultative services with PathWay-Lean

PathWay-Lean is a consultative service provided to health care institutions by Abbott Diagnostics specialists and certified Lean & Six Sigma consultants. They can help you to streamline your workflow and enhance laboratory efficiency and productivity. For further information on how we can share visions in the future please visit us at the EUROMEDLAB 2009, Abbott booth No. 42.



Adorini Luciano

Intercept Pharmaceuticals, Corciano (PG), Italy

E-mail: LAdorini@interceptpharma.com

Baerlocher Gabriela

Hematology, University Hospital Bern, Switzerland

E-mail: gabriela.baerlocher@insel.ch

Bais Renze

Laboratory Medicine Services Northern Sydney Central Coast (PaLMS), Hospital, St Leonards, Sydney, Australia

E-mail: rbais@med.usyd.edu.au

Benga Gheorghe

Department of Cell and Molecular Biology, "Iuliu Hatieganu" University of Medicine and Pharmacy Cluj-Napoca, Romania

E-mail: gbenga@umfcluj.ro

Bennett Mike

Department of Pathology & Laboratory Medicine, University of Pennsylvania & The Children's Hospital of Philadelphia, Philadelphia, USA

E-mail: bennettmi@email.chop.edu

Berger Thomas

Neuroimmunological and Multiple Sclerosis Clinic & Research Unit, Clin. Dept. Of Neurology, Innsbruck Medical University, Innsbruck, Austria

E-mail: Thomas.berger@i-med.ac.at

Beskow Anna

Karolinska Institutet Biobank, Stockholm Sweden

E-mail: anna.beskow@ki.se

Bidart Jean Michel

Translational Research Laboratory, Institut de Cancérologie Gustave Roussy, Villejuif France

E-mail: jean-michel.bidart@igr.fr

Bidlingmaier Martin

Medizinische Klinik - Innenstadt, Ludwig-Maximilians-University, Munich, Germany

E-mail: Martin.Bidlingmaier@med.uni-muenchen.de

Bilic-Zulle Lidija

Department of Medical Informatics, Rijeka University School of Medicine, Croatia

E-mail: lbilicz@medri.hr

Bizzaro Nicola

Laboratorio di Patologia Clinica, Ospedale S. Antonio, Tolmezzo, Italy

E-mail: nbizzaro@ass3.sanita.fvg.it

Blaton Vic

Az St Jan Av, Department Clinical Chemistry, Brugge Belgium

E-mail: victor.blaton@skynet.be

Bogdanos Dimitrios P.BP.

Liver Immunopathology, Institute of Liver Studies, King's College London

E-mail: Dimitrios.bogdanos@kcl.ac.uk

Bohr Vilhelm

Laboratory of Molecular Gerontology, National Institute on Aging, Baltimore, USA

E-mail: BohrV@grc.nia.nih.gov

Bossuyt Patrick MM

University of Amsterdam, the Netherlands

E-mail: p.m.bossuyt@amc.nl

Boyd James C.

Department of Pathology, University of Virginia Health System, Virginia, USA

E-mail: jboyd@virginia.edu

Burnett David

Consultant in Quality and Accreditation Systems, Penarth, United Kingdom.

E-mail: davidburnett4@btinternet.com

Celis Julio E.

Institute of Cancer Biology, Danish Cancer Society and Danish Centre for Translational Breast Cancer Research (DCTB), Copenhagen, Denmark.

E-mail: jec@cancer.dk

Cerioti Ferruccio

Diagnostica e Ricerca San Raffaele, Italy

E-mail: cerioti.ferruccio@hsr.it

Charpentier Guillaume

Diabetology & Endocrinology Unit, Centre Hospitalier Sud Francilien, Hôpital Gilles de Corbeil - Corbeil-Essonnes.

E-mail: guillaume.charpentier@ch-sud-francilien.fr

Chiba Peter

Institute of Medical Chemistry, Medical University of Vienna, Austria

E-mail: peter.chiba@meduniwien.ac.at

Christenson Robert H.

University Of Maryland School Of Medicine,
Baltimore, USA

E-mail: rchristenson@umm.edu

Clark Penelope

The Regional Endocrine Laboratory,
Department of Clinical Biochemistry,
University Hospital Birmingham NHS
Foundation Trust, Birmingham, UK

Email: Penelope.clark@uhb.nhs.uk

Collinson Paul

Clinical Blood Sciences, Department of
Cardiology, St Georges Hospital, London, UK

E-mail: paul.collinson@stgeorges.nhs.uk

Cross Heide

Dept. of Pathophysiology, Medical University
of Vienna, Austria

E-mail: heide.cross@meduniwien.ac.at

Decaux Guy

Erasme University Hospital, Brussels,
Belgium

E-mail: guy.decaux@skynet.be

Delvin Edgard

Chief of Department Clinical Biochemistry, Ste
Justine Hospital, University of Montreal,
Canada

E-mail: edgard.delvin@recherche-ste-justine.qc.ca

Dequeker Els

Center of Human Genetics, University
Hospital UZ Leuven, University of Leuven,
Belgium

E-mail: els.dequeker@med.kuleuven.be

Ehrmeyer Sharon

Pathology and Laboratory Medicine,
University of Wisconsin School of Medicine
and Public Health, Madison, USA

E-mail: ehrmeyer@wisc.edu

Forest Jean Claude

Department of Medical Biology, Faculty of
Medicine, Laval University, and Human
Reproduction, Maternal and Child Health Unit,
Research Center, Quebec City University
Medical Center, Quebec City, Canada

E-mail: jean-claude.forest@bcx.ulaval.ca

Gamba Gerardo

Molecular Physiology Unit. Instituto Nacional
de Ciencias Medicas y Nutricion Salvador
Zubiran and Instituto de Investigaciones
Biomedicas, Universidad Nacional Autonoma
de Mexico. Mexico City, Mexico

E-mail: gamba@biomedicas.unam.mx

Giannitsis Evangelos

Medizinische Klinik III, Universitätsklinikum
Heidelberg, Germany

E-mail: evangelos.giannitsis@med.uni-heidelberg.de

Gillery Philippe

Laboratory of Pediatric Biology and Research,
University Hospital of Reims, France

E-mail: pgillery@chu-reims.fr

Gouget Bernard

Fédération Hospitalière de France

E-mail: b.gouget@fhf.fr

Grabher-Stöffler Gertrud

Psychiatrisches Krankenhaus, Austria

E-mail: gertrud.grabher-stoeffler@tilak.at

Graus Francesc

MD. Barcelona, Spain

E-mail: fgraus@clinic.ub.es

Green Anthony R

University of Cambridge, Department of
Haematology, CIMR, Cambridge, UK

E-mail: arg1000@cam.ac.uk

Grey Vijay

P.I. for the Hamilton site, Department of
Pathology and Laboratory Medicine,
McMaster University, Hamilton, ON, Canada

E-mail: grey@hhsc.ca

Griesmacher Andrea

Central Institute of Medical and Chemical
Laboratory Diagnostics, University Hospital of
Innsbruck, Austria

E-mail: andrea.griesmacher@uki.at

Grubb Anders

Department of Clinical Chemistry, University
Hospital, Lund, Sweden

E-mail: anders.grubb@med.lu.se

Guchelaar Henk-Jan

Dept. Clinical Pharmacy and Toxicology,
Leiden University Medical Centre, The
Netherlands

E-mail: H.J.Guchelaar@lumc.nl

Hansson Lars-Olof

Karolinska Hospital, Karolinska Institution

E-mail: lasse.hansson@bonetmail.com

lasse.hansson@me.com

Henny Joseph

Laboratoire de Biologie Clinique, Centre de
Médecine Préventive, Vandoeuvre-lès-Nancy,
France

E-mail: joseph.henny@cmp.u-nancy.fr

Herold Manfred

Medical University of Innsbruck, Dept. Internal
Medicine 1, Austria

E-mail: manfred.herold@i-med.ac.at

Hochstrasser Denis

Department of genetics and Laboratory
Medicine, Service of Laboratory Medicine,
Toxicology laboratory, Geneva University
Hospital, Switzerland

E-mail: denis.Hochstrasser@dim.hcuge.ch

Hoeijmakers Jan H.J.

MGC, CBG, Genetics, Erasmus MC,
Rotterdam, The Netherlands

E-mail: j.hoeijmakers@erasmusmc.nl

Hofmann Walter

Department for Clinical Chemistry,
Städtisches Klinikum München, Munich,
Germany

E-mail: walter.hofmann@klinikum-muenchen.de

Holt David

Analytical Unit, St George's - University of
London, London, United Kingdom

E-mail: dholt@sgul.ac.uk

Horvath Rita Andrea

Department of Clinical Chemistry, University
of Szeged, Medical Faculty, Albert Szent-
Györgyi Clinical Centre, Szeged, Hungary

E-mail: ahorvath@clab.szote.u-szeged.hu

Huber Andreas R

Center of Laboratory Medicine, Kantonsspital,
Aarau, Switzerland

E-mail: andreas.huber@ksa.ch

Huisman Wim

Department of Clinical Chemistry, Medical
Centre Haaglanden, The Hague, The
Netherlands

E-mail: w.huisman@mchaaglanden.nl

Humbel R. Louis

Laboratoire Luxembourgeois
d'Immunopathologie, Alzette, Luxembourg

E-mail: rlhumbel@llip.lu

Ivaska Kaisa K.

University of Turku, Institute of Biomedicine,
Department of Cell Biology and Anatomy,
Turku, Finland

E-mail: kaisa.ivaska@utu.fi

Jabor Antonin

Department of Laboratory Medicine, Institute
for Clinical and Experimental Medicine,
Prague, Czech Republic

E-mail: antonin.jabor@ikem.cz

Jones Patti

Departments of Pathology and Medical
Laboratory Science, University of Texas
Southwestern Medical Center and Children's
Medical Center, Dallas, Texas, USA

E-mail: patti.jones@childrens.com

Kampf Caroline

Human Proteome Resource project,
Department of Genetics and Pathology,
Uppsala, Sweden

E-mail: caroline.kampf@genpat.uu.se

Karsdal Morten Asser

Nordic Bioscience, Herlev, Denmark

E-mail: mk@Nordicbioscience.com

Kastelein John

Department of Vascular Medicine, Academic
Medical Center, Amsterdam, The Netherlands

E-mail: j.j.kastelein@amc.uva.nl

Katus Hugo A.

Medizinische Klinik III, Universitätsklinikum
Heidelberg, Germany

E-mail: hugo_katus@med.uni-heidelberg.de

Konstantinides Stavros

Department of Cardiology and Pulmonology,
Georg August University of Goettingen,
Germany

E-mail: skonstan@med.uni-goettingen.de

Langlois Michel

Department of Clinical Chemistry, AZ St-Jan Hospital, Bruges, Belgium

E-mail: michel.langlois@azbrugge.be

Lapolla Annunziata

Department of Clinical and Surgical Sciences-Chair of Metabolic Disease, Padova University, Italy

E-mail: annunziata.lapolla@unipd.it

Lehmann Craig

Health Sciences Center, Stony Brook University, Stony Brook, New York, USA

E-mail: clehmann@notes.cc.sunysb.edu

Lehmann Sylvain

CHRU/CNRS Montpellier, Montpellier, France.

E-mail: s-lehmann@chu-montpellier.fr

Li Ren-Ke

Toronto general Hospital, University of Toronto, Canada

E-mail: renkeli@uhnres.utoronto.ca

Lippi Giuseppe

Clinical Chemistry Section, University of Verona, Italy

E-mail: giuseppe.lippi@univr.it

Lorenc Roman S.

Department of Biochemistry and Experimental Medicine, The Children's Memorial Health Institute, Warsaw, Poland

E-mail: biochemia@czd.pl

Mair Johannes

Department of Internal Medicine III - Cardiology, Innsbruck Medical University, Innsbruck, Austria

E-mail: Johannes.Mair@i-med.ac.at

Marquet Pierre

INSERM U850, Univ Limoges, CHU Limoges, France

E-mail: pierre.marquet@unilim.fr

Maurer Hans

Department of Experimental and Clinical Toxicology, Saarland University, Homburg, Germany

E-mail: hans.maurer@uks.eu

McQueen Matthew J.

Department of Laboratory Medicine, Hamilton Health Sciences, Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada

E-mail: mcquemat@hhsc.ca

Meyer Helmut

Medizinisches Proteom-Center, Ruhr-University Bochum, Germany

E-mail: helmut.e.meyer@rub.de

Mocarelli Paolo

University Department of Laboratory Medicine, University Milano Bicocca and Hospital of Desio - 20030 Milano, Italy

E-mail: mocarelli@uds.unimib.it

Müller Mathias M.

Austrian Society of Quality Assurance and Standardization, Vienna, Austria

E-mail: mathias.mueller@oequasta.at

Nichols James

Department of Pathology, Baystate Health, Springfield, Massachusetts, USA

E-mail: james.nichols@bhs.org

Ozben Tomris

Akdeniz University, Medical Faculty, Antalya, Turkey

E-mail: ozben@akdeniz.edu.tr

Pacifici Roberta

Therapeutic Research and Medicine Evaluation Department, Istituto Superiore di Sanità, Rome, Italy

E-mail: roberta.pacifici@iss.it

Panteghini Mauro

Department of Clinical Sciences 'Luigi Sacco', University of Milan Medical School, Milano, Italy

E-mail: mauro.panteghini@unimi.it

Petzold Axel

Dept. of Neuroimmunology, UCL Institute of Neurology, Queen Square, London, United Kingdom

E-mail: a.petzold@ion.ucl.ac.uk

Pichini Simona

Therapeutic Research and Medicine Evaluation Department, Istituto Superiore di Sanità, Rome, Italy

E-mail: simona.pichini@iss.it

Pilz Stefan

Department of Internal Medicine, Division of Endocrinology and Nuclear Medicine, Medical University of Graz, Austria

Email: stefan.pilz@chello.at

Pirmohamed Munir

Department of Pharmacology, Ashton Street, The University of Liverpool, United Kingdom

E-mail: munirp@liverpool.ac.uk

Plebani Mario

Department of Laboratory Medicine,
University-Hospital of Padova, Italy
E-mail: mario.plebani@unipd.it

Pulkki Kari

Department of Clinical Chemistry, University
of Kuopio and Eastern Finland Laboratory
Centre, Kuopio, Finland
E-mail: kari.pulkki@hus.fi, kari.pulkki@islab.fi

Quehenberger Peter

Department of Medical and Chemical
Laboratory Diagnostics, University of Wien,
Austria
E-mail: peter.quehenberger@meduniwien.ac.at

Rothe Gregor

Laboratory Bremen, Germany
E-mail: gregor.rothe@laborzentrum-bremen.de

Ruel Marc

Cardiac Surgeon & Cardiac Surgery
Research Chair, University of Ottawa Heart
Institute, Canada
E-mail: mruel@ottawaheart.ca

Russo-Marie Françoise

Research Department, Genopole®, Evry,
France
E-mail: francoise.russo-marie@genopole.fr

Sandberg Sverre

Laboratory of Clinical Biochemistry,
Haukeland University Hospital, Bergen,
Norway
E-mail: sverre.sandberg@isf.uib.no

Schlingmann Peter K.

University Children's Hospital, Philipps
University, Marburg, Germany
E-mail: schlingm@med.uni-marburg.de

Schmitz Gerd

University Hospital Regensburg, Germany
E-mail: gerd.schmitz@klinik.uni-regensburg.de

Schussler Olivier

Ottawa Heart Institute, Division of Cardiac
Surgery, University of Ottawa, Canada
E-mail: oschussler@ottawaheart.ca

Schwarzinger Ilse

Department of Medical and Chemical
Laboratory Diagnostics, Medical University of
Vienna, Austria
E-mail: ilse.schwarzinger@meduniwien.ac.at

Sciacovelli Laura

Centro di Ricerca Biomedica, Castelfranco
Veneto (TV), Italy
E-mail: laura.sciacovelli@sanita.padova.it

Segura Jordi

BioAnalysis and Analytical Services Group,
Neuropsychopharmacology Program, IMIM-
Hospital del Mar, Universitat Pompeu Fabra,
Barcelona, Spain
E-mail: jsegura@imim.es

Shiloh Yossi

Department of Human Molecular Genetics
and Biochemistry, Sackler School of
Medicine, Tel Aviv University, Israel
E-mail: yossih@post.tau.ac.il

Simundic Ana-Maria

University Department of Chemistry,
University Hospital "Sestre Milosrdnice"
Zagreb, Croatia
E-mail: am.simundic@gmail.com

Sinha Pranav

IMCL, LKH-Klagenfurt, Austria
E-mail: pkosinha@gmx.net

Sonntag Oswald

Ortho Clinical Diagnostics, Central Europe,
Scientific Affairs, Neckargemuend, Germany
E-mail: osonntag@its.inj.com

Sperti-Furga Giulio

CEMM - Center for Molecular Medicine,
Vienna, Austria
E-mail: gsperti@cemm.oeaw.ac.at

Stekel Herbert

Zentrallabor AKH, Linz, Austria
E-mail: herbert.stekel@akh.linz.at

Sturgeon Catharine

Department of Clinical Biochemistry, Royal
Infirmary, Edinburgh, United Kingdom
E-mail: C.Sturgeon@ed.ac.uk

Sypniewska Grazyna

Department of Laboratory Medicine, NC
University, Bydgoszcz, Poland
E-mail: grazynaodes@interia.pl

Tailleux Anne

Institut Pasteur de Lille, Département
d'Athérosclérose, Inserm, Université Lille
Nord de France, Faculté des Sciences
Pharmaceutiques et Biologiques et Faculté de
Médecine, France
E-mail: anne.tailleux@univ-lille2.fr

Tauber Rudolf

Zentralinstitut für Laboratoriumsmedizin und Pathobiochemie, Institut für Molekularbiologie und Biochemie, Charité - Universitätsmedizin Berlin, Germany

E-mail: Rudolf.Tauber@charite.de

Thienpont Linda

Laboratory for Analytical Chemistry, Faculty of Pharmaceutical Sciences, Ghent University, Belgium

E-mail: linda.thienpont@ugent.be

Topic Elizabeta

University Department of Clinical, Sestre Milosrdnice University Hospital, Zagreb, Croatia

E-mail: elizabeta.topic@gmail.com

Valdes Roland

University of Louisville, USA

E-mail: rvaldes@louisville.edu

Van Dieijen-Visser Marja

University Hospital Maastricht, The Netherlands

E-mail: mp.van.dieijen.visser@mumc.nl

Van Schaftingen Emile

de Duve Institute and Universtair Catholique de Louvain, Brussels, Belgium

E-mail: emile.vanschaftingen@uclouvain.be

Van Schaik Ron

Dept. Clinical Chemistry, Erasmus MC, Rotterdam, the Netherlands

Email: r.vanschaik@erasmusmc.nl

Vinks Sanders

Divisions of Clinical Pharmacology, Cincinnati Children's Hospital Medical Center Cincinnati, Ohio, USA

E-mail: sander.vinks@cchmc.org

Wagner Oswald

Dept. of Medical and Chemical Laboratory Diagnostics, University of Wien, Austria

E-mail: oswald.wagner@meduniwien.ac.at

Whitfield John B.

Genetic Epidemiology Unit, Queensland Institute of Medical Research, Brisbane, Australia

Email: John.Whitfield@qimr.edu.au

Young Ian

Queen's University Belfast, Ireland

E-mail: I.Young@qub.ac.uk

Zatloukal Kurt

Medical University of Graz, Institut of Pathology, Graz, Austria

E-mail: kurt.zatloukal@medunigraz.at

Zinder Oren

Laboratory Medicine, Faculty of Medicine, The Technion, Haifa, Israel

E-mail: ozinder@matav.net.il